These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32799945)

  • 1. Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies.
    Lanari M; Anderson EJ; Sheridan-Pereira M; Carbonell-Estrany X; Paes B; Rodgers-Gray BS; Fullarton JR; Grubb E; Blanken M
    Epidemiol Infect; 2020 Aug; 148():e170. PubMed ID: 32799945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.
    Anderson EJ; Carbonell-Estrany X; Blanken M; Lanari M; Sheridan-Pereira M; Rodgers-Gray B; Fullarton J; Rouffiac E; Vo P; Notario G; Campbell F; Paes B
    Pediatr Infect Dis J; 2017 Feb; 36(2):160-167. PubMed ID: 27755464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
    Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
    Chi H; Chung CH; Lin YJ; Lin CH
    PLoS One; 2018; 13(5):e0197410. PubMed ID: 29746578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical burden of severe respiratory syncytial virus infection during the first 2 years of life in children born between 2000 and 2011 in Scotland.
    Thwaites R; Buchan S; Fullarton J; Morris C; Grubb E; Rodgers-Gray B; Coutts J
    Eur J Pediatr; 2020 May; 179(5):791-799. PubMed ID: 31912234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; Krilov LR; DeVincenzo JP; Checchia PA; Halasa N; Simões EA; Domachowske JB; Forbes ML; Pannaraj PS; McBride SJ; McLaurin KK; Kumar VR; Ambrose CS
    Am J Perinatol; 2017 Jan; 34(1):51-61. PubMed ID: 27233106
    [No Abstract]   [Full Text] [Related]  

  • 7. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
    Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T
    J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER; Winer IH; Oladapo A; Wojdyla M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
    Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
    Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
    Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics.
    Krilov LR; Anderson EJ
    J Perinatol; 2020 Aug; 40(8):1135-1144. PubMed ID: 32499597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
    J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR; Fergie J; Goldstein M; Brannman L
    Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants.
    Paes B; Fullarton JR; Rodgers-Gray BS; Carbonell-Estrany X
    Curr Med Res Opin; 2021 Jul; 37(7):1149-1153. PubMed ID: 33813989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants.
    Blanken MO; Paes B; Anderson EJ; Lanari M; Sheridan-Pereira M; Buchan S; Fullarton JR; Grubb E; Notario G; Rodgers-Gray BS; Carbonell-Estrany X
    Pediatr Pulmonol; 2018 May; 53(5):605-612. PubMed ID: 29405612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
    Goldstein M; Krilov LR; Fergie J; McLaurin KK; Wade SW; Diakun D; Lenhart GM; Bloomfield A; Kong AM
    Am J Perinatol; 2018 Dec; 35(14):1433-1442. PubMed ID: 29920638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.